NEW YORK, Jan. 8, 2024 /PRNewswire/ — The castration-resistant prostate cancer (CRPC) treatment market is expected to grow by USD 5.98 billion from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 8.83% during the forecast period, according to Technavio Research. The market has been segmented by distribution channels (hospital pharmacies, retail pharmacies, and online pharmacies), therapy (hormonal therapy, chemotherapy, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). North America is estimated to contribute 47% to the growth of the global market during the forecast period. Moreover, this region’s market growth is driven by high-quality healthcare infrastructure.
This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a Free PDF Sample Report
Company Profile:
Active Biotech AB, Allarity Therapeutics Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Astellas Pharma Inc., Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Everest Pharmaceuticals Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson, Medias Klinikum GmbH and Co. KG, Merck KGaA, Novartis AG, Pfizer Inc., Robotic Prostate Centre Cambridge, Sanofi SA, The Focal Therapy Clinic, and Ono Pharmaceutical Co. Ltd.
Allarity Therapeutics Inc. – The company offers Castration-Resistant Prostate Cancer CRPC treatments such as LiPlaCis and Irofulven, in Phase II trials.
To gain access to more company profiles available with Technavio, buy the report!
Castration-Resistant Prostate Cancer (CRPC) Treatment Market: Segmentation Analysis
The hospital pharmacies segment is estimated to witness significant growth during the forecast period. A specific category of pharmacies operating within the premises of a healthcare facility is included in this hospital pharmacy segment.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a Free PDF Sample Report
Castration-Resistant Prostate Cancer (CRPC) Treatment Market: Market Dynamics
Key Driver
The increasing Early detection of prostate cancer is a key factor driving market growth. This growth has intensified the use of Androgen Deprivation Therapy (ADT), Chemotherapy (including Docetaxel and cabazitaxel), and novel medications like Abiraterone Acetate, Enzalutamide, Radium-223 Dichloride. Additionally, the emergence of immunotherapy, PARP Inhibitors such as Olaparib, and advancements in targeted therapies focusing on Prostate-Specific Membrane Antigen (PSMA) are further catalyzing innovative treatment approaches for CRPC.
Leading Trend
The evolution of CRPC treatment options stands as a significant trend driving the growth of the Castration-Resistant Prostate Cancer (CRPC) Treatment Market. This evolution includes Clinical Trials, addressing Hormone Refractory Prostate Cancer and Metastatic CRPC (mCRPC), with a focus on Novel Therapeutics developed by Biopharmaceutical Companies. FDA Approvals of these treatments, alongside an emphasis on Personalized Medicine to combat Treatment Resistance Mechanisms, are shaping the landscape. Additionally, attention to Health Economics and Reimbursement aligns with improving Patient’s Quality of Life.
Significant Challenge
The prevalence of health complications linked to CRPC drugs emerges as a significant challenge impeding the Castration-Resistant Prostate Cancer (CRPC) Treatment Market growth. Challenges persist regarding Biomarkers in CRPC and Genetic Testing, impacting the efficacy of treatments like Radiopharmaceuticals and Bone-targeted Therapy. Market Trends and Forecasts, influenced by Healthcare Policies and Regulations, affect the Drug Development Pipeline and Oncology Research and Development, complicating Global Market Analysis within the CRPC treatment landscape.
Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information.
Related Reports
The fallopian tube cancer treatment market is estimated to generate a value of USD 998.75 million in 2018, anticipated to reach USD 2.14 billion by 2028.
The head and neck cancer treatment market size is estimated to grow by USD 5,077.38 million at a CAGR of 11.27% between 2022 and 2027.
What are the key data covered in this castration-resistant prostate cancer (CRPC) treatment market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the castration-resistant prostate cancer (CRPC) treatment market between 2023 and 2028.
- Precise estimation of the castration-resistant prostate cancer (CRPC) treatment market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the castration-resistant prostate cancer (CRPC) treatment market across North America, Europe, Asia, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of castration-resistant prostate cancer (CRPC) treatment market companies.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Distribution Channel
Market Segmentation by Therapy
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
